Related Experiment Video
Updated: Jun 23, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Nanomedicine Strategies for Rheumatoid Arthritis: Precision Delivery and Immune Microenvironment Modulation
Qian He1, Jinming Xing2, Jie Kang2
1Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, Shanxi, People's Republic of China.
Abstract:
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovial inflammation, pannus formation, and progressive joint destruction. Despite their established clinical benefits, conventional antirheumatic drugs remain hampered by poor targeting precision, systemic toxicity, and inadequate immunomodulation of the dysregulated microenvironment. The recent development of nanomedicine technology offers transformative potential to address these therapeutic challenges. This review comprehensively examines the application of advanced nano-platforms in RA management, with particular focus on their dual roles in precision drug delivery and immune microenvironment remodeling. The discussion encompasses multifunctional nanomaterials that enable precise drug transport while actively regulating pathological processes through reactive oxygen species scavenging, hypoxia mitigation, and immune cell reprogramming. Additionally, the integration of diagnostic and therapeutic functions within nanomaterial systems represents a significant advancement in RA theranostics. Finally, translational challenges and future directions are critically analyzed to map the clinical development path for intelligent RA nanomedicine.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Microorganisms in Medicine and Therapeutics
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
The Tumor Microenvironment